The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation.

MLA

Stadler, Nicole, et al. “The Bruton Tyrosine Kinase Inhibitor Ibrutinib Abrogates Triggering Receptor on Myeloid Cells 1-Mediated Neutrophil Activation.” Haematologica, vol. 102, no. 5, May 2017, pp. e191–94. EBSCOhost, https://doi.org/10.3324/haematol.2016.152017.

APA

Stadler, N., Hasibeder, A., Lopez, P. A., Teschner, D., Desuki, A., Kriege, O., Weber, A. N. R., Schulz, C., Michel, C., Heβ, G., & Radsak, M. P. (2017). The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation. Haematologica, 102(5), e191–e194. https://doi.org/10.3324/haematol.2016.152017

Chicago

Stadler, Nicole, Astrid Hasibeder, Pamela Aranda Lopez, Daniel Teschner, Alexander Desuki, Oliver Kriege, Alexander N R Weber, et al. 2017. “The Bruton Tyrosine Kinase Inhibitor Ibrutinib Abrogates Triggering Receptor on Myeloid Cells 1-Mediated Neutrophil Activation.” Haematologica 102 (5): e191–94. doi:10.3324/haematol.2016.152017.